US FDA inspection at Glenmark Pharmaceuticals Ltd's manufacturing facility in Goa, India

The United States Food & Drug Administration (U.S. FDA) conducted a GMP inspection at Glenmark Pharmaceuticals Limited's Manufacturing Facility situated in Goa from June 22, 2026 to June 30, 2026.

At the end of the inspection, the Company was issued a Form 483 with six observations. There was no observation related to data integrity reported. These observations are procedural in nature, and none are repeat observations.

The Company does not anticipate any impact on the supply of its commercial products. The Company will work in close collaboration with the Agency to address the observations and will respond to the U.S. FDA within the stipulated timeline.

Shares of Glenmark Pharmaceuticals Limited was last trading in BSE at Rs. 2204.90 as compared to the previous close of Rs. 2186.20. The total number of shares traded during the day was 12549 in over 1812 trades.

The stock hit an intraday high of Rs. 2220.05 and intraday low of 2184.35. The net turnover during the day was Rs. 27667447.00.

Source : Equity Bulls

Keywords

GlenmarkPharmaceuticals INE935A01035 USFDA Inspection Goa ManufacturingFacility